Fifth Third Bancorp
VIRX

Fifth Third Bancorp’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Fifth Third Bancorp’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2
Closed – – 2365
2016
Q1 		$0 Buy
+2
New +$303 ﹤0.01% 2715

Other funds holding VIRX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

Fifth Third Bancorp's VIRX Position: Q2 2016 in Review

Fifth Third Bancorp sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2016, closing a stake of 2 shares.

Fifth Third Bancorp first reported a position in VIRX in Q1 2016 and held it in 1 quarter. The position peaked at $0 in Q1 2016. 56 funds tracked by Wall St. Rank hold VIRX as of Q2 2016.

  • Fifth Third Bancorp reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
  • Fifth Third Bancorp sold 2 Viracta Therapeutics, Inc. Common Stock shares in Q2 2016.
  • Fifth Third Bancorp first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2016 and held it in 1 quarter.
  • Fifth Third Bancorp's Viracta Therapeutics, Inc. Common Stock position peaked at $0 in Q1 2016.
  • 56 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Fifth Third Bancorp's 13F filing for Q2 2016, filed 11 Aug 2016.